Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Boosted by Jacobs & Co. CA

Jacobs & Co. CA increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,166 shares of the medical research company’s stock after purchasing an additional 2,460 shares during the period. Jacobs & Co. CA’s holdings in Thermo Fisher Scientific were worth $7,519,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of TMO. Bornite Capital Management LP raised its position in Thermo Fisher Scientific by 50.0% during the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock valued at $17,719,000 after buying an additional 10,000 shares during the period. Fairfield Bush & CO. grew its holdings in shares of Thermo Fisher Scientific by 1.2% during the 1st quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after acquiring an additional 36 shares in the last quarter. Loomis Sayles & Co. L P increased its position in Thermo Fisher Scientific by 563.5% in the 1st quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock worth $11,721,000 after purchasing an additional 16,853 shares during the last quarter. Covestor Ltd increased its holdings in Thermo Fisher Scientific by 60.5% in the first quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock worth $190,000 after buying an additional 121 shares during the last quarter. Finally, Merit Financial Group LLC boosted its holdings in Thermo Fisher Scientific by 3.6% in the first quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock worth $395,000 after purchasing an additional 23 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last quarter. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.9 %

Shares of NYSE TMO opened at $579.37 on Thursday. The business has a fifty day moving average of $564.32 and a two-hundred day moving average of $519.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The stock has a market cap of $220.92 billion, a PE ratio of 37.50, a PEG ratio of 2.39 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.40 earnings per share. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Analysts Set New Price Targets

TMO has been the topic of a number of analyst reports. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price objective on the stock. Robert W. Baird reiterated an “outperform” rating and issued a $670.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Raymond James raised their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Finally, Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $599.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.